Steven Fontana - Academia.edu (original) (raw)
Papers by Steven Fontana
L'invention concerne des composes qui sont des conjugues de composes de polyether a membrure ... more L'invention concerne des composes qui sont des conjugues de composes de polyether a membrure en echelle et de composes biologiquement actifs ou de composes de recherche, des preparations pharmaceutiques comprenant lesdits conjugues et des procedes de transport desdits composes a travers des membranes biologiques.
L'invention concerne un procede qui permet de minimiser les pertes osseuses induites par un c... more L'invention concerne un procede qui permet de minimiser les pertes osseuses induites par un compose de formule (II) ou d'un sel pharmaceutiquement acceptable de ce compose administre a un mammifere ayant besoin d'un traitement. Selon ce procede, on administre au mammifere en meme temps ou successivement une quantite efficace d'un compose de formule (I) ou d'un de ses sels pharmaceutiquement acceptables. Dans la formule (I), les groupes R1 designent independamment les uns des autres -H, -OH, -O(alkyle C?1?-C4), -OCOC6H5, -OCO(alkyle C1-C6) ou -OSO2(alkyle C4-C6); et R?2? designe 1-piperidinyle, 1-pyrrolidinyle, methyl-1-pyrrolidinyle, dimethyl-1-pyrrolidinyle, 4-morpholino, dimethylamino, diethylamino ou 1-hexamethylene-imino. Selon un autre procede decrit qui permet de minimiser les pertes osseuses induites par l'administration d'un compose de formule (II), on administre en meme temps ou successivement un agent anabolique osseux. L'invention concerne ...
Gassman JACS 96, 5512 (1974). Miwa, et al., Med. Chem., 34, 555-560 (1991). Noell, C. W., et al.,... more Gassman JACS 96, 5512 (1974). Miwa, et al., Med. Chem., 34, 555-560 (1991). Noell, C. W., et al., J. Heterocyclic Chem., 1, 34-41 (1964). Kandasamy Ramasamy, et al., J. Chem. Soc. Chem. Commun. 560-562 (1989). Secrist, J. A., et al., J. Org. Chem, 43,3937-3941 (1978). DeGraw, J. I., et al., J. Med. Chem, 25, 1227-1230 (1982). Taylor, C. E., et al., J. Org. Chem, 55, 3222-3227 (1990). Primary Examiner-Mark L. Berch Attorney, Agent, or Firm-Robert A. Conrad; Steven A. Fontana; David E. Boone (57) ABSTRACT Processes for preparing 5-substituted pyrrolo2,3dpyrimidines which are useful as intermediates for the preparation of pyrrolo2,3-dipyrimidine antineoplastic agents or as antineoplastic agents themselves are pro vided.
PROBLEM TO BE SOLVED: To obtain a preparation containing a specific benzofuran derivative, effect... more PROBLEM TO BE SOLVED: To obtain a preparation containing a specific benzofuran derivative, effective for bone loss of female after climacteric, patients whose wombs are extracted, patients of long-term administration of corticosteroid, patients of Cushing syndrome and patients of growth abnormality of sexual organs, etc. SOLUTION: This preparation contains a compound of the formula (R is H or methyl; R 1 and R 2 are each methyl, ethyl or a saturated heterocyclic group forming group together with N bonded them; X is Br, Cl, F or H) (salt) {e.g. 2-(p-chlorobenzyl)-3-[p-(2-dimethylaminoethoxy)phenyl]-6-methoxy- benzo[b]furan}. The dose of the compound of generally about 0.1-1,000 mg/day (especially about 50-600 mg/day) and administered about once to about three times dividedly daily. The preparation has negligible adverse effects or has no adverse effects at all. COPYRIGHT: (C)1996,JPO
L'invention concerne des composes qui sont des conjugues de composes de polyether a membrure ... more L'invention concerne des composes qui sont des conjugues de composes de polyether a membrure en echelle et de composes biologiquement actifs ou de composes de recherche, des preparations pharmaceutiques comprenant lesdits conjugues et des procedes de transport desdits composes a travers des membranes biologiques.
L'invention concerne un procede qui permet de minimiser les pertes osseuses induites par un c... more L'invention concerne un procede qui permet de minimiser les pertes osseuses induites par un compose de formule (II) ou d'un sel pharmaceutiquement acceptable de ce compose administre a un mammifere ayant besoin d'un traitement. Selon ce procede, on administre au mammifere en meme temps ou successivement une quantite efficace d'un compose de formule (I) ou d'un de ses sels pharmaceutiquement acceptables. Dans la formule (I), les groupes R1 designent independamment les uns des autres -H, -OH, -O(alkyle C?1?-C4), -OCOC6H5, -OCO(alkyle C1-C6) ou -OSO2(alkyle C4-C6); et R?2? designe 1-piperidinyle, 1-pyrrolidinyle, methyl-1-pyrrolidinyle, dimethyl-1-pyrrolidinyle, 4-morpholino, dimethylamino, diethylamino ou 1-hexamethylene-imino. Selon un autre procede decrit qui permet de minimiser les pertes osseuses induites par l'administration d'un compose de formule (II), on administre en meme temps ou successivement un agent anabolique osseux. L'invention concerne ...
Gassman JACS 96, 5512 (1974). Miwa, et al., Med. Chem., 34, 555-560 (1991). Noell, C. W., et al.,... more Gassman JACS 96, 5512 (1974). Miwa, et al., Med. Chem., 34, 555-560 (1991). Noell, C. W., et al., J. Heterocyclic Chem., 1, 34-41 (1964). Kandasamy Ramasamy, et al., J. Chem. Soc. Chem. Commun. 560-562 (1989). Secrist, J. A., et al., J. Org. Chem, 43,3937-3941 (1978). DeGraw, J. I., et al., J. Med. Chem, 25, 1227-1230 (1982). Taylor, C. E., et al., J. Org. Chem, 55, 3222-3227 (1990). Primary Examiner-Mark L. Berch Attorney, Agent, or Firm-Robert A. Conrad; Steven A. Fontana; David E. Boone (57) ABSTRACT Processes for preparing 5-substituted pyrrolo2,3dpyrimidines which are useful as intermediates for the preparation of pyrrolo2,3-dipyrimidine antineoplastic agents or as antineoplastic agents themselves are pro vided.
PROBLEM TO BE SOLVED: To obtain a preparation containing a specific benzofuran derivative, effect... more PROBLEM TO BE SOLVED: To obtain a preparation containing a specific benzofuran derivative, effective for bone loss of female after climacteric, patients whose wombs are extracted, patients of long-term administration of corticosteroid, patients of Cushing syndrome and patients of growth abnormality of sexual organs, etc. SOLUTION: This preparation contains a compound of the formula (R is H or methyl; R 1 and R 2 are each methyl, ethyl or a saturated heterocyclic group forming group together with N bonded them; X is Br, Cl, F or H) (salt) {e.g. 2-(p-chlorobenzyl)-3-[p-(2-dimethylaminoethoxy)phenyl]-6-methoxy- benzo[b]furan}. The dose of the compound of generally about 0.1-1,000 mg/day (especially about 50-600 mg/day) and administered about once to about three times dividedly daily. The preparation has negligible adverse effects or has no adverse effects at all. COPYRIGHT: (C)1996,JPO